NCT02570711View on ClinicalTrials.gov

Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

October 13, 2015

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Metastatic Pancreatic Cancer
Interventions
DRUG

ACP-196

ACP-196 capsule

DRUG

Nab-paclitaxel

Nab-paclitaxel infusion

DRUG

Gemcitabine

Gemcitabine infusion

Trial Locations (10)

27710

Duke University Medical Center, Durham

33916

Florida Cancer Specialists, Fort Myers

37205

Tennessee Oncology, Nashville

37404

Tennessee Oncology, Chattanooga

44195

Cleveland Clinic, Cleveland

76104

The Center for Cancer and Blood Disorders, Fort Worth

77030

International Cancer Center, Houston

93003

Ventura Clinical Trials, Ventura

45242-5665

Oncology Hematology Care, Cincinnati

77030-4000

MD Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

Acerta Pharma BV
All Listed Sponsors
lead

Acerta Pharma BV

INDUSTRY